Core Viewpoint - The article discusses the advancements and market potential of radiofrequency ablation technology, particularly in the treatment of atrial fibrillation, highlighting the increasing demand driven by an aging population and the introduction of innovative products by Medtronic [1][3][7]. Summary by Sections Atrial Fibrillation and Market Demand - Atrial fibrillation (AF) is a common arrhythmia characterized by rapid and irregular heartbeats, affecting a large patient population. By 2025, the number of AF patients is expected to reach 22.67 million, with a compound annual growth rate (CAGR) of 2.85% from 2021 to 2025, indicating a high demand for surgical interventions [3][4]. Radiofrequency Ablation Overview - Traditional methods such as radiofrequency and cryoablation have become first-line treatments for AF. Radiofrequency ablation is noted for its effectiveness and safety, utilizing high-frequency electromagnetic waves to generate heat that destroys targeted tissue [4][6]. Market Growth and Drivers - The global radiofrequency ablation market was valued at approximately $2 billion in 2019 and is projected to grow to about $4 billion by 2027, with a CAGR of 8.5%. This growth is fueled by technological advancements, broader applications beyond cardiac diseases, and support from governments and healthcare institutions [7][10]. Medtronic's Product Innovations - Medtronic has introduced the PulseSelect system, a pulsed field ablation (PFA) product approved by NMPA, FDA, and CE, which is effective for both paroxysmal and persistent AF. Its design allows for targeted treatment with minimal damage to surrounding tissues [14][15][24]. - The Affera system, another Medtronic product, combines pulsed field and radiofrequency ablation, enhancing the precision and efficiency of cardiac procedures [23][28]. Medtronic Company Overview - Medtronic, established in 1949, is a leading global medical technology company with over 95,000 employees, focusing on chronic disease management across various medical fields. In the fourth fiscal quarter of 2025, the company reported net sales of $8.93 billion, up from $8.59 billion in the previous year [33][34].